2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.13 Xiao

PP01.13 Xiao - Abstract

Pdf Summary

The study reviewed patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received EGFR targeted therapy followed by immunotherapy (IO). A total of 59 patients were included, with the majority initially diagnosed with Stage IV disease and CNS metastasis. The median overall survival for the cohort was 38 months. Patients who received two EGFR targeted therapies had a significantly longer median overall survival compared to those who did not. When it came to immunotherapy, patients who received combination chemotherapy alongside IO had a longer progression-free survival compared to those who only received IO. Patients with "Atypical" EGFR mutations had better progression-free survival with IO therapy but lower with EGFR therapy compared to those with "Typical" mutations. The study concluded that patients did not show sustained response to IO monotherapy after progressing on EGFR targeted therapy, emphasizing the potential benefit of cytotoxic agents in this setting. Additionally, patients with rarer "Atypical" EGFR mutations may benefit from IO therapy.

Keywords

EGFR-mutated non-small cell lung cancer

EGFR targeted therapy

immunotherapy

Stage IV disease

CNS metastasis

overall survival

progression-free survival

combination chemotherapy

Atypical EGFR mutations

Typical EGFR mutations